Nodular sclerosis: Difference between revisions
m (Robot: Changing Category:Diseases to Category:Disease) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 6: | Line 6: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Nodular sclerosis''' (or "NSHL") is a form of [[Hodgkin's lymphoma]] which is the most common subtype of HL in developed countries. It usually affects females more than males and has a median age of onset at ~28 years. It is composed of large tumor nodules with lacunar [[Reed-Sternberg cell]] (RS cells) surrounded by fibrotic collagen bands. | '''Nodular sclerosis''' (or "NSHL") is a form of [[Hodgkin's lymphoma]] which is the most common subtype of HL in developed countries. It usually affects females more than males and has a median age of onset at ~28 years. It is composed of large tumor nodules with lacunar [[Reed-Sternberg cell]] (RS cells) surrounded by fibrotic collagen bands. | ||
| Line 13: | Line 13: | ||
==Reference== | ==Reference== | ||
{{reflist|2}} | |||
==External links== | ==External links== | ||
| Line 20: | Line 20: | ||
* [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11712426&dopt=Abstract PubMed] - use of [[Erythropoietin]] | * [http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11712426&dopt=Abstract PubMed] - use of [[Erythropoietin]] | ||
* [http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed.section.34158 Subtypes] | * [http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=cmed.section.34158 Subtypes] | ||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Latest revision as of 20:09, 4 September 2012
Template:DiseaseDisorder infobox
|
WikiDoc Resources for Nodular sclerosis |
|
Articles |
|---|
|
Most recent articles on Nodular sclerosis Most cited articles on Nodular sclerosis |
|
Media |
|
Powerpoint slides on Nodular sclerosis |
|
Evidence Based Medicine |
|
Cochrane Collaboration on Nodular sclerosis |
|
Clinical Trials |
|
Ongoing Trials on Nodular sclerosis at Clinical Trials.gov Trial results on Nodular sclerosis Clinical Trials on Nodular sclerosis at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Nodular sclerosis NICE Guidance on Nodular sclerosis
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Nodular sclerosis Discussion groups on Nodular sclerosis Patient Handouts on Nodular sclerosis Directions to Hospitals Treating Nodular sclerosis Risk calculators and risk factors for Nodular sclerosis
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Nodular sclerosis |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Nodular sclerosis (or "NSHL") is a form of Hodgkin's lymphoma which is the most common subtype of HL in developed countries. It usually affects females more than males and has a median age of onset at ~28 years. It is composed of large tumor nodules with lacunar Reed-Sternberg cell (RS cells) surrounded by fibrotic collagen bands.
The British National Lymphoma Investigation further categorized NSHL based upon Reed-Sternberg cells into "nodular sclerosis type I" (NS I) and "nodular sclerosis type II" (NS II), with the first subtype responding better to treatment. [1]
Reference
- ↑ Mauch, Peter (1999). Hodgkin's Disease. Lippincott Williams & Wilkins. p. 107. ISBN 0-7817-1502-4. Unknown parameter
|coauthors=ignored (help)